1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Embla Medical hf's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was -3.21%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Embla Medical hf's 1-Year ROIIC % or its related term are showing as below:
OSSFF's 1-Year ROIIC % is ranked worse than 55.04% of 823
companies
in the Medical Devices & Instruments industry
Industry Median: 0.36
vs OSSFF: -3.21
Embla Medical hf (OTCPK:OSSFF) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Embla Medical hf 1-Year ROIIC % Related Terms
Embla Medical hf 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Embla Medical hf's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf 1-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's 1-Year ROIIC % falls into.
Embla Medical hf's 1-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( 97.0493 (Mar. 2026) - 91.1007 (Mar. 2025) )
/
( 1575.854 (Mar. 2026) - 1441.198 (Mar. 2025) )
=
5.9486
/
134.656
=
4.42%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Embla Medical hf (OSSFF) has a 1-Year ROIIC % of -3.21 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Embla Medical hf and its competitors. According to the industry distribution chart, Embla Medical hf ranks #453 out of 823 companies in the Medical Devices & Instruments industry, placing it in the top 55%.
Is Embla Medical hf's 1-Year ROIIC % too high?
Embla Medical hf's current 1-Year ROIIC % is -3.21. Based on the distribution chart, Embla Medical hf ranks #453 out of 823 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's 1-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #453 out of 823 companies for 1-Year ROIIC %. This places Embla Medical hf in the lower half of its industry. The industry median 1-Year ROIIC % is 0.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Medical Devices & Instruments company?
The median 1-Year ROIIC % among Medical Devices & Instruments companies is 0.36, based on 823 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median 1-Year ROIIC % is 0.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current 1-Year ROIIC % is -3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current 1-Year ROIIC % of -3.21. The stock's GF Value™ is $5.29, compared to a current price of $4.15 — trading 21.6% below its estimated fair value. The current 1-Year ROIIC % is -3.21. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current 1-Year ROIIC % is -3.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 21.6% below its estimated GF Value™ of $5.29.
Key valuation signals for OSSFF:
1-Year ROIIC %: -3.21
GF Value™: $5.29 vs. price of $4.15 (21.6% below fair value)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
